

Board Changes

Next Science Limited (ASX:NXS) (“Next Science” or “the Company”) today announces that Non-Executive Director Dan Spira has informed the Board that he will not be seeking re-election at the upcoming Annual General Meeting (AGM).

Next Science is a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health.

Following more than six years as a Non-Executive Director of the Company, Mr Spira has decided to step down from the Board due to his professional commitments.

Next Science is continuing its search for a US-based independent non-executive director with relevant industry expertise.

Next Science’s Chair Aileen Stockburger said: “I would like to thank Dan for his service and the invaluable contribution he has made to Next Science since joining the Board in 2017. The Company has benefited from his deep knowledge of the consumer healthcare space as we transitioned from start up to commercialisation of our unique XBIO™ portfolio. We will continue our search for an additional US-based director as we focus on driving penetration of our wound care and surgical products in that market.”

Approved and authorised for release by the Board

Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company’s primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com